Drugs / IMIGLITAZAR
last change Dec 2004 re-read 2 minutes ago

IMIGLITAZAR

also known as TAK-559

Small molecule targets PPARA, PPARG via activation

Developed for
diabetes mellitus · type 2 diabetes mellitus
Investigated by
Takeda

Trials 6 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00762957 Nov → Dec 2004 diabetes mellitus Takeda Terminated No outcome recorded
Phase 3 NCT00762684 Nov → Dec 2004 type 2 diabetes mellitus Takeda Terminated No outcome recorded
Phase 3 NCT00759720 Nov 2003 → Dec 2004 diabetes mellitus Takeda Terminated No outcome recorded
Phase 3 NCT00763022 Nov 2003 → Dec 2004 type 2 diabetes mellitus Takeda Completed No outcome recorded
Phase 3 NCT00762190 Nov 2003 → Dec 2004 type 2 diabetes mellitus Takeda Terminated No outcome recorded
Phase 3 NCT00762112 Nov 2003 → Dec 2004 diabetes mellitus Takeda Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as IMIGLITAZAR ChEMBL registry synonym — accepted as the source's own label CHEMBL592054
Known as TAK-559 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00763022
5

NCT00762957

NCT00762112

NCT00762684

NCT00762190

NCT00759720

Action Activate “TAK-559 has partial peroxisome proliferator-activated receptor-alpha agonist activity, potent peroxisome proliferator-activated receptor-alpha activity, and modest peroxisome...” NCT00759720
2

“Peroxisome proliferator-activated receptor gamma agonist” CHEMBL592054

“Peroxisome proliferator-activated receptor alpha agonist” CHEMBL592054

Modality Small molecule “TAK-559 is a novel oxyiminoalkanoic acid under investigation for use as an oral agent in the treatment of patients with type 2 diabetes mellitus.” NCT00759720
Route Oral “TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.” NCT00759720
Target PPARA “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL592054
Target PPARG “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL592054